Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody

Abstract CNTO 5825 is a human anti‐interleukin‐13 ( IL ‐13) monoclonal antibody (m A b) that inhibits binding of human IL ‐13 to IL ‐13Rα1 and IL ‐13Rα2. The purpose of this investigation was to predict human pharmacokinetics ( PK ) of CNTO 5825 using different allometric approaches and non‐clinical PK data in order to select the right and safe doses for first‐in‐human ( FIH ) study. After intravenous ( IV ) administration of CNTO 5825, clearance ( CL ) ranged from 9.98 to 11.49 ml/day/kg in rats and from 5.78 to 7.19 ml/day/kg in cynomolgus monkeys. The volume of distribution at steady‐state (Vss) in rats was large (151.52–155.64 ml/kg) compared to cynomolgus monkey (49.77–61.10 ml/kg). The terminal half‐life ( T 1/2 ) ranged from 12.29 to 14.15 days in rats and from 6.61 to 7.73 days in cynomolgus monkeys. The PK of CNTO 5825 was linear in 1–10 mg/kg dose range in both species. The bioavailability after subcutaneous ( SC ) administration was 94% and 79% in rats and cynomolgus monkeys, respectively. The predicted CL and Vss based on allometric methods and PK data from rats and monkeys were within twofold of observed CL and Vss in human beings; the predicted CL and Vss in human beings (70 kg) based on time‐invariant method with combined PK data from rats and monkeys were 4.84 ± 1.13 ml/day/kg and 68.93 ± 35.55 ml/kg, respectively. The selected doses for the FIH study based on time‐invariant method and no observed adverse effect level in toxicity studies in rats and monkeys provided exposures that were subsequently shown to be well tolerated and safe in human beings.